Global Experts Rewrite the Rules on Colon Diverticular Disease Management
A 32-expert international consensus redefines diagnosis and treatment of diverticular disease, ending routine antibiotic use and personalizing surgery.
Summary
The Fiesole Consensus, developed by 32 gastroenterology experts from 14 countries, delivers the first truly global guidelines on colonic diverticular disease. Using a structured Delphi process and GRADE methodology, the panel clarifies that diverticulosis — pouches in the colon without symptoms — needs no treatment, while symptomatic diverticular disease may benefit from dietary fiber, selected probiotics, mesalazine, and rifaximin. Critically, routine antibiotics for uncomplicated acute diverticulitis are no longer recommended. Elective surgery should be individualized based on quality of life rather than number of episodes. Risk factors identified include smoking, obesity, NSAIDs, corticosteroids, opioids, and immunotherapy, while high fiber intake is protective. CT imaging remains the gold standard for complicated cases. Future research priorities include microbiome profiling and genetic risk assessment.
Detailed Summary
Colonic diverticulosis — the formation of small pouches in the colon wall — is the most common structural abnormality of the colon in developed countries, and its global prevalence is rising with aging populations and westernized diets. About 20–25% of people with diverticulosis develop symptomatic diverticular disease, which ranges from mild discomfort to life-threatening complications. Given the scale of the problem and evolving scientific understanding, updated international guidance was urgently needed.
The Fiesole Consensus brought together 32 specialists from 14 countries, including gastroenterologists, surgeons, radiologists, and epidemiologists. They applied a structured Delphi consensus process grounded in the PICO framework and GRADE evidence-rating methodology to generate recommendations across five domains: epidemiology and pathogenesis, clinical features, diagnosis, medical therapy, and surgical management.
A central finding is the clear distinction between diverticulosis (asymptomatic pouches requiring no intervention) and diverticular disease (symptomatic or complicated pouches requiring treatment). High dietary fiber intake emerged as the primary protective factor, while smoking, obesity, NSAIDs, corticosteroids, opioids, and immunotherapy agents all increase disease risk. For symptomatic uncomplicated disease, fiber supplementation, specific probiotics, mesalazine, and the gut-selective antibiotic rifaximin may offer symptom relief.
Perhaps the most practice-changing recommendation is the abandonment of routine antibiotic prescribing for acute uncomplicated diverticulitis — a significant shift from historical practice. For complicated cases, CT imaging is preferred over ultrasound. Elective surgical decisions should prioritize patient quality of life over the number of prior episodes, moving away from older episode-count thresholds.
The guidelines also chart a research agenda focusing on gut microbiome characterization, genetic risk profiling, and long-term outcomes of selective antimicrobial and surgical strategies — areas with direct relevance to personalized and preventive medicine in aging populations.
Key Findings
- Routine antibiotics are no longer recommended for acute uncomplicated diverticulitis, reversing longstanding practice.
- High dietary fiber intake is protective; smoking, obesity, NSAIDs, opioids, and immunotherapy raise disease risk.
- Symptomatic uncomplicated diverticular disease may improve with fiber, probiotics, mesalazine, or rifaximin.
- Elective surgery should be individualized by quality of life, not by number of diverticulitis episodes.
- CT imaging is preferred for complicated cases; ultrasound is acceptable only in experienced hands.
Methodology
This international consensus involved 32 experts from 14 countries using a structured Delphi process based on the PICO framework and GRADE methodology. Recommendations span five clinical domains: epidemiology, clinical features, diagnosis, medical therapy, and surgical management. The study is a consensus guideline, not a primary clinical trial, so findings reflect expert synthesis of existing evidence.
Study Limitations
The guidelines are based on consensus and evidence synthesis rather than new primary data, limiting certainty in areas with sparse high-quality trials. Access to only the abstract restricts full evaluation of individual recommendation strength and supporting evidence grades. Some recommendations may not translate equally across diverse global healthcare systems with variable diagnostic resources.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: